EUVIMEDSkopri EUVIMED
Crossref

Site-specific oral controlled release metformin tablets - development, in vitro, ex vivo and in vivo evaluation

The Internet Journal of Pharmacology · 2010

DOI: 10.5580/1571 ↗

At a glance

Journal article in The Internet Journal of Pharmacology, 2010.

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Oral absorption of metformin is confined to the upper part of intestine posing problems in the formulation of extended release tablets. Therefore, the objective of the present study was to develop controlled-release mucoadhesive core tablets and confine the tablets to the specific site in the gastrointestinal tract. A projective coat protects the core tablets from mucoadhesion till the targeted site is reached. Once the tablet reaches the specific site, the coat dissolves exposing the core tablet for mucoadhesion. In vitro coat intactness test and ex vivo tablet bioadhesion test confirmed that the tablets were targeted and contained in the upper intestine. Further, the pharmacokinetic parameters obtained for metformin from the site-specific coated formulation were better (P

Cite

APA

(2010). Site-specific oral controlled release metformin tablets - development, in vitro, ex vivo and in vivo evaluation. The Internet Journal of Pharmacology. https://doi.org/10.5580/1571

Vancouver

Site-specific oral controlled release metformin tablets - development, in vitro, ex vivo and in vivo evaluation. The Internet Journal of Pharmacology. 2010. doi:10.5580/1571

BibTeX
@article{euvimed2010,
  title = {Site-specific oral controlled release metformin tablets - development, in vitro, ex vivo and in vivo evaluation},
  journal = {The Internet Journal of Pharmacology},
  year = {2010},
  doi = {10.5580/1571}
}
Start for free →